XNAS · Healthcare · Biotechnology
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.20 | -0.19 | +5.00% | $215,000 | ✅ Beat | -18.78% | -3.65% | — |
| 2026-03-24 | Q4 2025 | -0.17 | -0.20 | -17.65% | $650,000 | ❌ Miss | -13.95% | -0.33% | +31.89% |
| 2025-11-12 |
| Q3 2025 |
| -0.20 |
| -0.20 |
| +0.00% |
| $378,000 |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.20 | -0.24 | -20.00% | $593,000 | ❌ Miss | -9.41% | -11.78% | -7.74% |
| 2025-03-18 | Q4 2024 | -0.23 | -0.25 | -8.70% | $665,000 | ❌ Miss | -3.25% | -0.32% | +0.32% |
| 2024-08-14 | Q2 2024 | -0.19 | -0.22 | -15.79% | $1.3M | ❌ Miss | +10.99% | +16.62% | +4.56% |
| 2024-05-14 | Q1 2024 | -0.21 | -0.22 | -4.76% | $898,000 | ❌ Miss | -0.10% | -0.83% | -9.52% |
| 2024-03-21 | Q4 2023 | -0.24 | -0.25 | -4.17% | $338,000 | ❌ Miss | — | — | — |
Showing last 8 quarters.